Note: Ingredients listed on restricted chemical lists
EC/CAS
202-049-5/91-20-3
Name of the chemical
Naphthalene,3
Concentration
0.1 - 0.24
General Information
Version
7.0
Revision date
2024-06-24
Product name
WOLF GASOLINE TREATMENT
1.2.1 Relevant identified uses
Industrial use,Professional use,Consumer use Industrial/Professional use spec Non-dispersive use Used in closed systems
Emergency telephone
0032 (0)3 870 00 00, +353 1 809 2566, +353 1 809 2166, +972 4 854 1900, +356 2545 6508, +46 10 456 6700
Icons in SDS
Company Information
company name
WOLF OIL CORPORATION N.V
e-mail address of the competent person responsible for the Safety Data Sheet
msds@wolfoil.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317, H319, H412
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
No additional information available
2.2 Label elements
Labelling
Hazard pictograms
GHS07
Signal word
Warning
Contains
Monoesterification products of alkenylalkanoic anhydride and 2-(dialkylamino)ethanol
Hazard statements
H317 - May cause an allergic skin reaction. H319 - Causes serious eye irritation. H412 - Harmful to aquatic life with long lasting effects.
Precautionary statements
P261 - Avoid breathing dust, fume, gas, mist, spray, vapours. P273 - Avoid release to the environment. P280 - Wear eye protection, face protection, protective clothing, protective gloves. P333+P313 - If skin irritation or rash occurs: Get medical advice/attention. P337+P313 - If eye irritation persists: Get medical advice/attention. P501 - Dispose of contents/container in accordance with local/regional/national/international regulations.
2.3 Other hazards
Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %
